Bile acid metabolomics reveals distinct immunometabolic niches and enables accurate diagnosis of AQP4-IgG–seronegative NMOSD - Takeaways - MDSpire

Bile acid metabolomics reveals distinct immunometabolic niches and enables accurate diagnosis of AQP4-IgG–seronegative NMOSD

  • By

  • Zixin Chen

  • Yuchen Ye

  • Yanping Lan

  • Kengna Fan

  • Xiaxia Qiu

  • Renquan Jiang

  • Xin Yang

  • Xinyao Yang

  • Xinrong Lu

  • Qunfang Huang

  • Yujue He

  • Can Liu

  • Qishui Ou

  • Zhen Xun

  • May 4, 2026

  • 0 min

Share

  • 1

    Bile acid metabolomics can differentiate NMOSD from MS, particularly in AQP4-IgG seronegative cases.

  • 2

    Serum bile acid profiles showed significant variations between NMOSD and MS, with distinct metabolic signatures.

  • 3

    A diagnostic framework utilizing bile acids achieved an AUC of 0.874 for distinguishing NMOSD from MS.

  • 4

    Deoxycholic acid demonstrated a high discriminative ability (AUC 0.965) for AQP4-IgG seronegative NMOSD.

  • 5

    Bile acid profiles correlated with neurological impairment, indicating their potential as biomarkers for NMOSD.

Original Source(s)

Bile acid metabolomics reveals distinct immunometabolic niches and enables accurate diagnosis of AQP4-IgG–seronegative NMOSD

  • by Zixin Chen, Yuchen Ye, Yanping Lan, Kengna Fan, Xiaxia Qiu, Renquan Jiang, Xin Yang, Xinyao Yang, Xinrong Lu, Qunfang Huang, Yujue He, Can Liu, Qishui Ou, Zhen Xun

  • May 4, 2026

Related Content

CSF Proteomics Identifies New Biomarkers for Multiple Sclerosis

Large-cohort CSF proteomics from the Mann Lab identifies a 22-protein panel distinguishing MS from related diseases

  • March 11, 2026

  • 3 min
The quality of life in Ecuadorian patients with multiple sclerosis and neuromyelitis optica spectrum disorder and their association with anxiety, depression, fatigue, and disability

Oral BTK Inhibitor Shows Disability Benefit in Progressive Multiple Sclerosis Trial

Phase 3 results show fenebrutinib matched OCREVUS on disability progression in PPMS

  • February 17, 2026

  • 3 min